a)NIAC recommends the passive immunisation of all infants against RSV during their first RSV season. Two forms of passive immunisation for infants against RSV have recently been authorised in the EU; a long-acting monoclonal antibody (nirsevimab) which can be administered to the infant directly, and a maternal vaccine RSV preF (Abrysvo, Pfizer) which can provide infant protection through transplacental antibody transfer. Both products have acceptable safety and efficacy profiles. Further analysis of cost effectiveness and programmatic considerations is required to determine the most appropriate RSV passive immunisation strategy for Irish infants. 

b)Once available, nirsevimab should replace palivizumab for those high-risk infants and children who are currently eligible to receive palivizumab.


a)NIAC recommends RSV vaccination for those aged 65 years and older with either RSVPreF3 (Arexvy, GSK) or RSV preF (Abrysvo, Pfizer). Both these products have similar safety and efficacy profiles. Further analysis of cost and product availability is needed to determine which product is more suitable for use in Ireland. 

b)Vaccine administration should aim to take place prior to the anticipated start of the RSV season where possible. 

c)In the event of limited supply of vaccines, priority should be given to those of more advanced age, those with significant comorbidities and those living in long term care facilities for older adults as they are at the highest risk of severe RSV disease. 

  • Recommendation
  • Europe
  • Ireland
  • Older adults
  • Children
  • RSV (Respiratory syncytial virus)